IN2014DN09546A - - Google Patents
Info
- Publication number
- IN2014DN09546A IN2014DN09546A IN9546DEN2014A IN2014DN09546A IN 2014DN09546 A IN2014DN09546 A IN 2014DN09546A IN 9546DEN2014 A IN9546DEN2014 A IN 9546DEN2014A IN 2014DN09546 A IN2014DN09546 A IN 2014DN09546A
- Authority
- IN
- India
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/446,328 US8653090B2 (en) | 2008-03-12 | 2012-04-13 | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents |
| PCT/US2013/036326 WO2013155385A1 (en) | 2012-04-13 | 2013-04-12 | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09546A true IN2014DN09546A (enExample) | 2015-07-17 |
Family
ID=49328189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9546DEN2014 IN2014DN09546A (enExample) | 2012-04-13 | 2014-11-13 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2836217A4 (enExample) |
| JP (1) | JP2015518000A (enExample) |
| CN (1) | CN104394872A (enExample) |
| IN (1) | IN2014DN09546A (enExample) |
| WO (1) | WO2013155385A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10736557B2 (en) | 2016-03-30 | 2020-08-11 | Brain F.I.T. Imaging, LLC | Methods and magnetic imaging devices to inventory human brain cortical function |
| US11337631B2 (en) | 2017-10-03 | 2022-05-24 | Brainn F.I.T. Imaging, LLC | Methods and magnetic imaging devices to inventory human brain cortical function |
| EP3946034A4 (en) | 2019-04-03 | 2023-01-11 | Brain F.I.T. Imaging, LLC | METHODS AND MAGNETIC TOMOGRAPHY DEVICES FOR THE INVENTORY OF CORCOAL FUNCTION OF THE HUMAN BRAIN |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6130035A (en) * | 1998-02-20 | 2000-10-10 | Brusilow Enterprise Llc | Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening |
| US6979688B2 (en) * | 2002-02-12 | 2005-12-27 | Ford John P | Treatment method against side-effects of chemotherapy |
| US6995165B2 (en) * | 2002-02-12 | 2006-02-07 | Ford John P | Methods, compositions, and kits for organ protection during systemic anticancer therapy |
| GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
| US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
| US7470672B2 (en) * | 2006-07-31 | 2008-12-30 | Savvipharm Inc. | Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives |
-
2013
- 2013-04-12 CN CN201380031029.XA patent/CN104394872A/zh active Pending
- 2013-04-12 WO PCT/US2013/036326 patent/WO2013155385A1/en not_active Ceased
- 2013-04-12 EP EP13775759.7A patent/EP2836217A4/en not_active Withdrawn
- 2013-04-12 JP JP2015505934A patent/JP2015518000A/ja active Pending
-
2014
- 2014-11-13 IN IN9546DEN2014 patent/IN2014DN09546A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015518000A (ja) | 2015-06-25 |
| CN104394872A (zh) | 2015-03-04 |
| EP2836217A1 (en) | 2015-02-18 |
| EP2836217A4 (en) | 2015-10-28 |
| WO2013155385A1 (en) | 2013-10-17 |